Cell-Free (cfDNA) Based Evaluation of KRAS Mutation Profile in Solid Tumors With Focus on G12C Variant

Saved in:

Bibliographic Details
Main Authors:	S. Limaye, S. Rajappa, A. Gaya, R. Ajami, R. Vijayakumar, A. Vaid, D. Akolkar, D. Patil, V. Datta, R. Datar, M. Cristofanilli
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	The Journal of Liquid Biopsy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195423000383
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Somatic Mutation Calling from cfDNA Using Machine Learning
by: S. Akbarinejad, et al.
Published: (2023-11-01)

cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations
by: A. Peleg, et al.
Published: (2023-11-01)

Plasma mutation profile of precursor lesions and colorectal cancer using the Oncomine Colon cfDNA Assay
by: Mariana Bisarro dos Reis, et al.
Published: (2024-12-01)

Impact of Liquid Biopsy Preanalytics on cfDNA Fragmentation Analyses
by: A. Hallermayr, et al.
Published: (2023-11-01)

Mutational spectrum of breast cancer by shallow whole-genome sequencing of cfDNA and tumor gene panel analysis.
by: Fernando Ambriz-Barrera, et al.
Published: (2024-01-01)

Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients
by: Yidan Ma, et al.
Published: (2024-09-01)

Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review
by: Keerthi Ranganathan, et al.
Published: (2024-09-01)

Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients
by: İrem Peker Eyüboğlu, et al.
Published: (2024-01-01)

Impact of cfDNA Input on Enzymatic Methylation Conversion and Library Preparation Robustness
by: U. Kunej, et al.
Published: (2023-11-01)

Interfacial cfDNA Enrichment and Amplification with On‐Chip Thermoplasmonics for Highly Sensitive Cancerous Liquid Biopsy
by: Danhua Wang, et al.
Published: (2025-01-01)

Comprehensive Analysis of Preanalytical Parameters in cfDNA from Lung, Colon, and Breast Cancer Patients
by: V. Denninghoff, et al.
Published: (2023-11-01)

Utility of Ultra-Low-Pass Whole Genome Sequencing in Bile CfDNA for the Management of Patients With Biliary Strictures
by: M. Arechederra, et al.
Published: (2023-11-01)

5‐Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma
by: Weiwei Xie, et al.
Published: (2024-12-01)

Early detection of canine hemangiosarcoma via cfDNA fragmentation and copy number alterations in liquid biopsies using machine learning
by: Soohyun Ko, et al.
Published: (2025-01-01)

Development of Automated cfDNA Extraction From Various Plasma Volumes and Implications on Sensitivity and Reproducibility of qPCR and dPCR Analysis
by: T. Hampshire, et al.
Published: (2023-11-01)

Role of silent mutations in KRAS-mutant tumors
by: Jun Lu, et al.
Published: (2025-02-01)

cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer
by: Gary Amseian, et al.
Published: (2024-12-01)

The opposite association of HRAS and KRAS mutations with clinical variables of bladder cancer
by: M. P. Smal, et al.
Published: (2015-12-01)

Viral mimicry evasion: a new role for oncogenic KRAS mutations
by: Raymond Chen, et al.
Published: (2025-02-01)

KRAS mutations in patients with AML: clinical characteristics and not reported mutations using NGS
by: Salma Said Ibrahim Elsayed, et al.
Published: (2024-12-01)

The clinical value of Serum hyaluronic acid, procollagen III, N-terminal propeptide levels sST2 and cfDNA in predicting the myocardial damage in children with severe pneumonia
by: Haoran Jia, et al.
Published: (2025-01-01)

Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification
by: Thamer Abdulhamid Aljuhani, et al.
Published: (2024-11-01)

KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
by: Sarah Bouri, et al.
Published: (2020-01-01)

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01)

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
by: Shangshang Ma, et al.
Published: (2024-12-01)

Copper-Mediated −CF(OCF3)(CF2H) Transfer to Organic Electrophiles
by: Behnaz Ghaffari, et al.
Published: (2024-09-01)

Effect of KRAS mutation status on clinicopathological characteristics and overall survival in patients with rectal cancer
by: Shengbin Zheng, et al.
Published: (2025-01-01)

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
by: Daniele Calistri, et al.
Published: (2006-01-01)

cfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infections in general practice: a study protocol for a prospective cohort study
by: Dorothea Dehnen, et al.
Published: (2022-06-01)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
by: Kohei Maruyama, et al.
Published: (2025-01-01)

Association of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues
by: Vahideh Hamidi Sofiani, et al.
Published: (2024-12-01)

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
by: Nicolas Piton, et al.
Published: (2015-01-01)

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer
by: Guomin Gu, et al.
Published: (2024-12-01)

Probable autoimmune lymphoproliferative syndrome with monogenic lupus due to KRAS mutation - A rare encounter
by: Amiya Nayak, et al.
Published: (2024-02-01)

Genetic feature diversity of KRAS-mutated colorectal cancer and the negative association of DNA mismatch repair deficiency relevant mutational signatures with prognosis
by: Ruichuan Shi, et al.
Published: (2025-01-01)

The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report
by: Ahmed N. Alkhasawneh, et al.
Published: (2012-01-01)

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
by: Linyan Tian, et al.
Published: (2025-01-01)

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells
by: Dominic Leiser, et al.
Published: (2015-08-01)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
by: Ullas Batra, et al.
Published: (2023-02-01)

KRAS Mutations, Potential Biomarkers for the Identification of Non-small-Cell Lung Cancer Patients That May Benefit From Immunotherapy-Based Treatments
by: L. Robado De Lope, et al.
Published: (2023-11-01)